Biocon Ltd reported a 56.8% drop in Q4 net profit to Rs 198.6 crore, impacted by an Rs 80.4 crore excepti ...More

Biocon Ltd reported a 56.8% drop in Q4 net profit to Rs 198.6 crore, impacted by an Rs 80.4 crore exceptional item. Despite this, consolidated revenue grew to Rs 4,516.6 crore. For FY26, net profit declined to Rs 368.8 crore, though revenue rose to Rs 16,927 crore. ...Less

Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebound ...More

Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the previous quarter. The results included a Rs 20 crore gratuity credit and a Rs 25 crore exceptional loss from employee termination benefits, alongside management changes. ...Less

Biocon Q4 Results: Revenue from operations increased 16% year-on-year (YoY) to Rs 2,947 crore in the Janu ...More

Biocon Q4 Results: Revenue from operations increased 16% year-on-year (YoY) to Rs 2,947 crore in the January-March 2024 period. ...Less

Consolidated revenue from operations in the fourth quarter stood at Rs 2,408.8 crore as against Rs 1,842. ...More

Consolidated revenue from operations in the fourth quarter stood at Rs 2,408.8 crore as against Rs 1,842.1 crore in the year-ago period, it added. ...Less

The board has recommended a final dividend payout of Rs 1.50 per share. In FY23, Biocon’s revenue grew al ...More

The board has recommended a final dividend payout of Rs 1.50 per share. In FY23, Biocon’s revenue grew almost 37% to Rs 11,174 crore, while its net profit fell nearly 29% to Rs 463 crore. The biosimilars business segment more than doubled its year-on-year revenue to INR2,102 crore in Q4 2022. ...Less

Total revenue grew 1% YoY to Rs 3,966 crore. EBITDA for the quarter declined 16% YoY to Rs 964 crore, rep ...More

Total revenue grew 1% YoY to Rs 3,966 crore. EBITDA for the quarter declined 16% YoY to Rs 964 crore, representing an EBITDA margin of 24% versus 29% in the same period last year. The gross R&D spends declined 36% YoY to Rs 228 crore in Q4FY24. ...Less

Biocon's board has also approved issue of bonus shares in the proportion of 1:1. ...More

Biocon's board has also approved issue of bonus shares in the proportion of 1:1. ...Less

For the fiscal year 2020-21, Biocon reported a 1 per cent decline in net profit to Rs 740 crore; while re ...More

For the fiscal year 2020-21, Biocon reported a 1 per cent decline in net profit to Rs 740 crore; while revenue grew 14 per cent to Rs 7360 crore. ...Less

Biocon reported a significant surge in Q4 net profit, up 153% to Rs 344 crore, with revenue growing 12% t ...More

Biocon reported a significant surge in Q4 net profit, up 153% to Rs 344 crore, with revenue growing 12% to Rs 4,454 crore. The company's biosimilars achieved impressive global sales, and strategic expansions, including a US manufacturing facility acquisition, are underway. Looking ahead, Biocon is focused on growth through innovation, digital augmentation, and operational excellence, including expanding its GLP-1 portfolio. ...Less

Biocon's shares surged by 8% on Tuesday due to strong Q4 earnings growth. Net profit grew by 31% to INR 3 ...More

Biocon's shares surged by 8% on Tuesday due to strong Q4 earnings growth. Net profit grew by 31% to INR 313 crore with 57% YoY growth in consolidated revenue from operations totaling INR 3,774 crore. Operating profit EBITDA surged 75% while gross spending on R&D rose by 53% to INR 356 crore. The biosimilars business stood out with revenue more than doubling on YoY basis to INR 2,102 crore. However, despite strong results, Biocon reportedly missed estimates, according to Motilal Oswal. ...Less

Indian biopharmaceutical company Biocon posted a 31% year-on-year rise in Q4 FY23 net profit, at INR313 c ...More

Indian biopharmaceutical company Biocon posted a 31% year-on-year rise in Q4 FY23 net profit, at INR313 crore ($41.9m), driven by successful biosimilar and research services businesses. The company registered INR239 crore in the same quarter of the prior financial year. Biocon's revenue from operations was up 56.7% YoY to INR3,734 crore, and its core EBITDA rose 56% YoY to INR1,260 crore. Biocon Biologics -- the company's biosimilar vertical -- saw a YoY growth of 114% with revenues at INR2,102 crore. ...Less

For the financial year 2019-20, the biopharma company posted a 15% growth in revenue at Rs 6,529 crore. ...More

For the financial year 2019-20, the biopharma company posted a 15% growth in revenue at Rs 6,529 crore. ...Less

Biocon shares: The company also reported consolidated revenue of Rs 4,454 crore, reflecting a 15% year-on ...More

Biocon shares: The company also reported consolidated revenue of Rs 4,454 crore, reflecting a 15% year-on-year increase on a like-for-like basis. Operating revenue, excluding BFI contributions, rose 15% to Rs 4,417 crore. ...Less

Biocon share price: Biocon reported a 96% year-on-year (YoY) decline in net profit, which fell to Rs 25 c ...More

Biocon share price: Biocon reported a 96% year-on-year (YoY) decline in net profit, which fell to Rs 25 crore in Q3FY25. In comparison, the company had posted a net profit of Rs 660 crore in Q3FY24, boosted by an exceptional item of Rs 566 crore. ...Less